MAPS raising money for PTSD research

MAPS raising money for PTSD research
facebooktwittergoogle_plus

The Multidisciplinary Association for Psychedelic Studies, or MAPS, won federal approval in March to conduct “whole plant” research on marijuana with the goal of making an FDA approved prescription drug for PTSD suffers, the first such research approval in history. MAPS is also undertaking an eight-year, $18.5 million plan to make MDMA into a federally approved PTSD medicine by 2021. To find out more about MAPS and efforts to develop psychedelic therapy into a legal prescription treatments, CRN’s Brian Bahouth spoke with MAPS Director of Communications, Brad Burge.